[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643520":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":41,"locations":52,"responsibleParty":71,"collaborators":32,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":32,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":32,"enrollmentInfo":83,"targetDuration":32,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":32,"overallStatus":93,"whyStopped":32,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Mongi Slim Hospital","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group C (Control):","PLACEBO_COMPARATOR","Group C (Control): Patients receive 4 mL of 0.9% isotonic normal saline",[13],"Drug: Group C (Control)",{"label":15,"type":16,"description":17,"interventionNames":18},"Group O (Ondansetron)","EXPERIMENTAL","Group O (Ondansetron): Patients receive 8 mg of ondansetron",[19],"Drug: Ondansetron 8 mg",{"label":21,"type":22,"description":23,"interventionNames":24},"Group L (Lidocaine)","ACTIVE_COMPARATOR","Group L (Lidocaine): Patients received 40 mg of lidocaine",[25],"Drug: Lidocaine %2 ampoule",[27,33,37],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Group C (Control)","Group C (Control): Patients receive 4 mL of 0.9% isotonic normal saline (placebo) administered intravenously over 5 minutes, ending 1 minute before anesthetic induction.",[9],null,{"type":28,"name":34,"description":35,"armGroupLabels":36,"otherNames":32},"Ondansetron 8 mg","Patients received 8 mg of ondansetron diluted to a total volume of 4 mL, administered intravenously over 5 minutes, ending 1 minute before anesthetic induction.",[15],{"type":28,"name":38,"description":39,"armGroupLabels":40,"otherNames":32},"Lidocaine %2 ampoule","Patients received 40 mg of lidocaine diluted with 0.9% normal saline to a total volume of 4 mL, administered intravenously over 5 minutes, ending 1 minute before anesthetic induction.",[21],[42,48],{"name":43,"role":44,"phone":45,"phoneExt":46,"email":47},"Mhamed Sami Mebazaa, professor","CONTACT","22252589","00216","msmebazaa@gmail.com",{"name":49,"role":44,"phone":50,"phoneExt":46,"email":51},"Amani Ben Haj youssef, assistant","96874336","amani.benhajyoussef@fmt.utm.tn",[53],{"facility":5,"status":32,"city":54,"state":32,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Tunis","2046","Tunisia","TN",{"type":59,"coordinates":60},"Point",[61,62],10.16579,36.81897,{"lat":62,"lon":61},[65,67,68],{"name":66,"role":44,"phone":50,"phoneExt":32,"email":51},"Amani Ben Haj youssef",{"name":32,"role":44,"phone":32,"phoneExt":32,"email":51},{"name":69,"role":70,"phone":32,"phoneExt":32,"email":32},"Amani Ben Haj youssef, Assistant","PRINCIPAL_INVESTIGATOR",{"type":70,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Mhamed Sami Mebazaa","Professor head of anesthesiology and ICU department","100643520","ondansetron-versus-lidocaine-for-preventing-pain-on-propofol-injection-100643520",false,"NCT07632144","Ondansetron Versus Lidocaine for Preventing Pain on Propofol Injection.","Ondansetron Versus Lidocaine for Preventing Pain on Propofol Injection: a Randomized Controlled Trial.","Inclusion Criteria:\n\n* The study included patients who met all of the following criteria:\n\nAged 18 years or older; Classified as ASA physical status I-III (Appendix 1); Provided written informed consent to participate in the study; Scheduled for elective surgery requiring general anesthesia with propofol induction.\n\nExclusion Criteria:\n\n* Patients were not eligible for inclusion if they:\n\nHad received analgesics or antiemetics within 12 hours before surgery; Had communication difficulties or were unable to assess pain adequately (e.g., language barrier, dementia, impaired consciousness); Had a known allergy to ondansetron, lidocaine, or propofol; Did not receive propofol for anesthetic induction; Were pregnant or breastfeeding; Suffered from chronic pain or regularly used opioid medications; Did not have a 20-gauge intravenous catheter inserted on the dorsum of the hand; Declined participation in the study.\n\nPatients were excluded from the study if they experienced any complication during anesthetic induction, including:\n\nAnaphylactic shock or allergic reaction to study medications; Hemodynamic or respiratory instability.\n\nPatients who subsequently withdrew their consent were also excluded from the study.","ALL","18 Years",{"count":84,"type":85},156,"ESTIMATED","INTERVENTIONAL",[88],"NA","This is a prospective, single-center, randomized, double-blind controlled trial involving patients scheduled for elective surgery requiring general anesthesia with propofol induction. Participants are randomly assigned to one of three groups: the ondansetron group (8 mg IV), the lidocaine group (40 mg IV), or the control group (0.9% normal saline placebo). Study medications are administered intravenously over 5 minutes, ending 1 minute before anesthetic induction.\n\nthe goal: To assess the efficacy of intravenous ondansetron versus lidocaine and placebo in reducing the incidence and intensity of pain associated with propofol injection in patients undergoing general anesthesia.",[91,92],"Anesthesia Induction","Propofol Pain Injection","NOT_YET_RECRUITING","2026-06-02",{"date":96,"type":97},"2026-06-08","ACTUAL",{"date":96,"type":85},{"date":100,"type":85},"2026-08-15",{"name":5,"class":6},1]